Natco Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 5, 2025, 4:52 pm

Quick Insight

Natco Pharma Ltd, currently trading at 855 per share with a market cap of 15,318 Cr., exhibits a P/E ratio of 9.02 and robust return on equity (ROE) and return on capital employed (ROCE) at 28.0% and 32.8%, respectively. The company's operational performance is strong with an operating profit margin (OPM) of 43%, supported by a healthy net profit of 1,883 Cr. Notably, Natco Pharma has substantial reserves of 7,571 Cr. and a comfortable interest coverage ratio (ICR) of 97.89x, indicating sound financial health. With a price-to-book value (P/BV) ratio of 2.91x and a cash conversion cycle (CCC) of 362 days, Natco Pharma presents an attractive investment opportunity in the pharmaceutical sector, underpinned by its solid fundamentals and financial stability.

Competitors of Natco Pharma Ltd

All Competitor Stocks of Natco Pharma Ltd

Quarterly Result

Last Updated: August 20, 2025, 6:25 am

Below is a detailed analysis of the quarterly data for Natco Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,329.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,221.00 Cr. (Mar 2025) to 1,329.00 Cr., marking an increase of 108.00 Cr..
• For Expenses, as of Jun 2025, the value is 758.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 673.00 Cr. (Mar 2025) to 758.00 Cr., marking an increase of 85.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 571.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2025) to 571.00 Cr., marking an increase of 23.00 Cr..
• For OPM %, as of Jun 2025, the value is 43.00%. The value appears to be declining and may need further review. It has decreased from 45.00% (Mar 2025) to 43.00%, marking a decrease of 2.00%.
• For Other Income, as of Jun 2025, the value is 62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 66.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 4.00 Cr..
• For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 7.00 Cr..
• For Depreciation, as of Jun 2025, the value is 58.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 98.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 40.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 572.00 Cr.. The value appears strong and on an upward trend. It has increased from 506.00 Cr. (Mar 2025) to 572.00 Cr., marking an increase of 66.00 Cr..
• For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be improving (decreasing) as expected. It has decreased from 20.00% (Mar 2025) to 16.00%, marking a decrease of 4.00%.
• For Net Profit, as of Jun 2025, the value is 480.00 Cr.. The value appears strong and on an upward trend. It has increased from 406.00 Cr. (Mar 2025) to 480.00 Cr., marking an increase of 74.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 26.84. The value appears strong and on an upward trend. It has increased from 22.70 (Mar 2025) to 26.84, marking an increase of 4.14.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:40 pm

Growth

Last Updated: September 5, 2025, 11:35 am

Balance Sheet

Last Updated: June 16, 2025, 11:39 am

Below is a detailed analysis of the balance sheet data for Natco Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 36.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 36.00 Cr..
• For Reserves, as of Mar 2025, the value is 7,571.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,817.00 Cr. (Mar 2024) to 7,571.00 Cr., marking an increase of 1,754.00 Cr..
• For Borrowings, as of Mar 2025, the value is 279.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 371.00 Cr. (Mar 2024) to 279.00 Cr., marking a decrease of 92.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 744.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 682.00 Cr. (Mar 2024) to 744.00 Cr., marking an increase of 62.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 8,631.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,906.00 Cr. (Mar 2024) to 8,631.00 Cr., marking an increase of 1,725.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 2,698.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,491.00 Cr. (Mar 2024) to 2,698.00 Cr., marking an increase of 207.00 Cr..
• For CWIP, as of Mar 2025, the value is 225.00 Cr.. The value appears strong and on an upward trend. It has increased from 137.00 Cr. (Mar 2024) to 225.00 Cr., marking an increase of 88.00 Cr..
• For Investments, as of Mar 2025, the value is 474.00 Cr.. The value appears to be declining and may need further review. It has decreased from 539.00 Cr. (Mar 2024) to 474.00 Cr., marking a decrease of 65.00 Cr..
• For Other Assets, as of Mar 2025, the value is 5,234.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,739.00 Cr. (Mar 2024) to 5,234.00 Cr., marking an increase of 1,495.00 Cr..
• For Total Assets, as of Mar 2025, the value is 8,631.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,906.00 Cr. (Mar 2024) to 8,631.00 Cr., marking an increase of 1,725.00 Cr..

Notably, the Reserves (7,571.00 Cr.) exceed the Borrowings (279.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Natco Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 77.34. This value is within the healthy range. It has increased from 39.18 (Mar 23) to 77.34, marking an increase of 38.16.
• For Diluted EPS (Rs.), as of Mar 24, the value is 77.34. This value is within the healthy range. It has increased from 39.18 (Mar 23) to 77.34, marking an increase of 38.16.
• For Cash EPS (Rs.), as of Mar 24, the value is 87.99. This value is within the healthy range. It has increased from 48.17 (Mar 23) to 87.99, marking an increase of 39.82.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 326.99. It has increased from 267.06 (Mar 23) to 326.99, marking an increase of 59.93.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 326.99. It has increased from 267.06 (Mar 23) to 326.99, marking an increase of 59.93.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 223.40. It has increased from 148.33 (Mar 23) to 223.40, marking an increase of 75.07.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 105.00. This value is within the healthy range. It has increased from 57.00 (Mar 23) to 105.00, marking an increase of 48.00.
• For PBIT / Share (Rs.), as of Mar 24, the value is 94.56. This value is within the healthy range. It has increased from 48.02 (Mar 23) to 94.56, marking an increase of 46.54.
• For PBT / Share (Rs.), as of Mar 24, the value is 93.49. This value is within the healthy range. It has increased from 47.23 (Mar 23) to 93.49, marking an increase of 46.26.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 77.56. This value is within the healthy range. It has increased from 39.19 (Mar 23) to 77.56, marking an increase of 38.37.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 77.56. This value is within the healthy range. It has increased from 39.19 (Mar 23) to 77.56, marking an increase of 38.37.
• For PBDIT Margin (%), as of Mar 24, the value is 47.00. This value is within the healthy range. It has increased from 38.42 (Mar 23) to 47.00, marking an increase of 8.58.
• For PBIT Margin (%), as of Mar 24, the value is 42.33. This value exceeds the healthy maximum of 20. It has increased from 32.37 (Mar 23) to 42.33, marking an increase of 9.96.
• For PBT Margin (%), as of Mar 24, the value is 41.85. This value is within the healthy range. It has increased from 31.83 (Mar 23) to 41.85, marking an increase of 10.02.
• For Net Profit Margin (%), as of Mar 24, the value is 34.71. This value exceeds the healthy maximum of 10. It has increased from 26.42 (Mar 23) to 34.71, marking an increase of 8.29.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 34.71. This value exceeds the healthy maximum of 20. It has increased from 26.42 (Mar 23) to 34.71, marking an increase of 8.29.
• For Return on Networth / Equity (%), as of Mar 24, the value is 23.71. This value is within the healthy range. It has increased from 14.67 (Mar 23) to 23.71, marking an increase of 9.04.
• For Return on Capital Employeed (%), as of Mar 24, the value is 28.52. This value is within the healthy range. It has increased from 17.61 (Mar 23) to 28.52, marking an increase of 10.91.
• For Return On Assets (%), as of Mar 24, the value is 20.10. This value is within the healthy range. It has increased from 12.64 (Mar 23) to 20.10, marking an increase of 7.46.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.03 (Mar 23) to 0.06, marking an increase of 0.03.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.63. It has increased from 0.50 (Mar 23) to 0.63, marking an increase of 0.13.
• For Current Ratio (X), as of Mar 24, the value is 4.14. This value exceeds the healthy maximum of 3. It has decreased from 4.39 (Mar 23) to 4.14, marking a decrease of 0.25.
• For Quick Ratio (X), as of Mar 24, the value is 3.42. This value exceeds the healthy maximum of 2. It has increased from 3.30 (Mar 23) to 3.42, marking an increase of 0.12.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.72. This value is below the healthy minimum of 4. It has increased from 0.63 (Mar 23) to 0.72, marking an increase of 0.09.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 12.25. This value is below the healthy minimum of 20. It has decreased from 14.03 (Mar 23) to 12.25, marking a decrease of 1.78.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 10.80. This value is below the healthy minimum of 20. It has decreased from 11.42 (Mar 23) to 10.80, marking a decrease of 0.62.
• For Earning Retention Ratio (%), as of Mar 24, the value is 87.75. This value exceeds the healthy maximum of 70. It has increased from 85.97 (Mar 23) to 87.75, marking an increase of 1.78.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 89.20. This value exceeds the healthy maximum of 70. It has increased from 88.58 (Mar 23) to 89.20, marking an increase of 0.62.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 97.89. This value is within the healthy range. It has increased from 71.74 (Mar 23) to 97.89, marking an increase of 26.15.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 73.31. This value is within the healthy range. It has increased from 50.33 (Mar 23) to 73.31, marking an increase of 22.98.
• For Enterprise Value (Cr.), as of Mar 24, the value is 16,442.15. It has increased from 9,905.31 (Mar 23) to 16,442.15, marking an increase of 6,536.84.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.11. This value exceeds the healthy maximum of 3. It has increased from 3.66 (Mar 23) to 4.11, marking an increase of 0.45.
• For EV / EBITDA (X), as of Mar 24, the value is 8.75. This value is within the healthy range. It has decreased from 9.52 (Mar 23) to 8.75, marking a decrease of 0.77.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 3.80 (Mar 23) to 4.26, marking an increase of 0.46.
• For Retention Ratios (%), as of Mar 24, the value is 87.74. This value exceeds the healthy maximum of 70. It has increased from 85.96 (Mar 23) to 87.74, marking an increase of 1.78.
• For Price / BV (X), as of Mar 24, the value is 2.91. This value is within the healthy range. It has increased from 2.11 (Mar 23) to 2.91, marking an increase of 0.80.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 3.80 (Mar 23) to 4.26, marking an increase of 0.46.
• For EarningsYield, as of Mar 24, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 23) to 0.08, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness